GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Notes Receivable

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Notes Receivable : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Notes Receivable?

Telomir Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.


Telomir Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Telomir Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Notes Receivable Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Notes Receivable
- - -

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

Telomir Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Telomir Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines